Smith & Nephew shares soar as activist Cevian builds stake
Cevian's 5% stake to make it no.2 shareholder in S+N
S+N shares rise to top of FTSE 100
Cevian sees potential by improving operating performance
S+N says will continue talks with Cevian
Adds analyst quote in paragraphs 10-11
By Yadarisa Shabong
July 4 (Reuters) -Shares in Smith & Nephew SN.L rose 7% to the top of the FTSE 100 index on Thursday after activist investor Cevian Capital disclosed a 5% stake in the British medical equipment maker, a filing showed.
Cevian, whose newly disclosed holding would make it Smith & Nephew's second largest shareholder according to LSEG data, is known for taking stakes in companies and calling for change.
Smith & Nephew, which makes orthopaedic implants, wound dressings and other surgical materials, has lost more than 50% of its stock value from an all-time high hit in February 2020.
Pandemic lockdowns that led to surgery delays and supply-related disruptions from COVID times, as well as high raw material costs due to the Russia-Ukraine conflict, have taken a toll on the company, which has struggled to grow its margins.
"Smith & Nephew owns fundamentally attractive businesses in structurally growing markets, but the company has not generated shareholder value for many years," Friederike Helfer, a partner at Cevian Capital, said in a statement.
"Cevian sees the potential to create significant long-term value by improving the operating performance of the company’s businesses. We have high expectations for the board and management to realize this potential," he added.
Smith & Nephew's FTSE 100 shares have struggled to eke out yearly gains for the past four years.
The group said it would continue to engage with Cevian "as we dowith all of ourshareholders", without providing further details as the conversations are private.
In 2022, it started a transformation plan that aimed to grow its hip and knee implant, wound management and sports medicines businesses while expanding margins.
"Cevian is likely to hold management's feet to the fire and may look for more ambitious targets than set out under the existing improvement plan," AJ Bell analyst Russ Mould said.
"It could also push for a rationalisation of the company’s portfolio."
Cevian is No.3 shareholder in Irish building materials firm CRH CRH.N, which last year ditched its primary London listing in favour of New York.
It is also the top shareholder in global education group Pearson PSON.L, which had reportedly faced investor pressure last year to move its listing.
Cevian sold down its entire stake in British insurer Aviva AV.L last year and ended its campaign to drive up investor payouts at the FSTE 100 company.
Smith & Nephew shares were up 7% to 1,057 pence by 1016 GMT.
Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman, Nivedita Bhattacharjee and Jan Harvey
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
